论文部分内容阅读
目的探讨检测系统性红斑狼疮(SLE)患者血清游离DNA的临床意义。方法采用分支DNA(bDNA)技术检测69例SLE患者(SLE组)、26例RA患者(RA组)和41例健康人(C组)血清游离DNA浓度,分析SLE患者抗dsDNA抗体、抗SmD1抗体、补体、24-h尿蛋白定量、C反应蛋白、血沉和SLE疾病活动指数(SLEDAI)与血清游离DNA浓度的相关性。结果与C组和RA组相比,SLE组患者血清游离DNA水平增高(P<0.01)。SLE组抗SmD1抗体阳性患者的血清游离DNA水平高于抗SmD1抗体阴性者(P<0.05)。SLE患者血清游离DNA浓度与血清抗dsDNA抗体、SLEDAI、血沉呈负相关(P<0.05),而与24-h尿蛋白定量、补体、C反应蛋白无明显相关性(P>0.05)。结论血清游离DNA检测可用于评估SLE病情进展。
Objective To investigate the clinical significance of detecting serum free DNA in patients with systemic lupus erythematosus (SLE). Methods The serum free DNA of 69 SLE patients (SLE group), 26 RA patients (RA group) and 41 healthy subjects (C group) were detected by bDNA technique. The levels of anti-dsDNA antibody, anti-SmD1 antibody , Complement, 24-h urinary protein, C-reactive protein, erythrocyte sedimentation rate, and SLE disease activity index (SLEDAI) and serum free DNA concentration. Results Compared with group C and group RA, the levels of serum free DNA in SLE group were significantly increased (P <0.01). The levels of serum free DNA in SLE patients with positive anti-SmD1 antibody were higher than those in patients with anti-SmD1 antibody negative (P <0.05). Serum free DNA concentration in patients with SLE was negatively correlated with serum anti-dsDNA antibody, SLEDAI and erythrocyte sedimentation rate (P <0.05), but not with quantitative, complement and C-reactive protein in 24-h urinary protein. Conclusion Serum free DNA test can be used to evaluate the progression of SLE.